DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Ildiko MadurkaAlexander VishnevskyJoan B SorianoStephanus J GansDanilo Joel Salazar OreAdrian RendonCharlotte S UlrikSushma BhatnagarSrikanth KrishnamurthyKirsten Mc HarryTobias WelteAlberto A FernandezBeata MehesKarin MeiserEwa GatlikUlrike SommerGuido JungeEderlon Rezendenull nullPublished in: Infection (2022)
ClinicalTrials.gov, NCT04382053.